Corina Dutcus, Senior Vice President and Head of Oncology Clinical Development at Eisai US, shared on LinkedIn:
“As an oncologist, I have come to appreciate that every regulatory milestone carries a deeply human meaning: years of scientific curiosity, rigorous clinical research, and, most importantly, the trust that patients place in us when they choose to participate in clinical trials.
The FDA approval on September 24th for certain adults with advanced renal cell carcinoma (RCC) is an important moment for the kidney cancer community.
It marks Eisai’s third FDA approval in RCC, reflecting our longstanding commitment to those living with RCC, built over many years of research spanning multiple lines of therapy, diverse patient populations, and a range of combination approaches.
That heritage, and the dedication of the investigators, study teams, and colleagues behind it, is what makes moments like this possible.
While we celebrate this achievement, our work continues.
We remain committed to building on the science, deepening our understanding of kidney cancer, and pursuing new opportunities to improve outcomes for patients facing difficult-to-treat diseases.”
You can also read: FDA Approved Belzutifan Plus Lenvatinib in Advanced ccRCC
